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Abstract
Aberrant increases in NMDA receptor (NMDAR) signaling contributes to central nervous system 
sensitization and chronic pain by activating neuronal nitric oxide synthase (nNOS) and generating 
nitric oxide (NO). Because the scaffolding protein postsynaptic density 95kDA (PSD95) tethers 
nNOS to NMDARs, the PSD95-nNOS complex represents a therapeutic target. Small molecule 
inhibitors IC87201 (EC5O: 23.94 µM) and ZL006 (EC50: 12.88 µM) directly inhibited binding of 
purified PSD95 and nNOS proteins in AlphaScreen without altering binding of PSD95 to ErbB4. 
Both PSD95-nNOS inhibitors suppressed glutamate-induced cell death with efficacy comparable 
to MK-801. IC87201 and ZL006 preferentially suppressed phase 2A pain behavior in the formalin 
test and suppressed allodynia induced by intraplantar complete Freund’s adjuvant administration. 
IC87201 and ZL006 suppressed mechanical and cold allodynia induced by the chemotherapeutic 
agent paclitaxel (ED50s: 2.47 and 0.93 mg/kg i.p. for IC87201 and ZL006, respectively). Efficacy 
of PSD95-nNOS disruptors was similar to MK-801. Motor ataxic effects were induced by 
MK-801 but not by ZL006 or IC87201. Finally, MK-801 produced hyperalgesia in the tail-flick 
test whereas IC87201 and ZL006 did not alter basal nociceptive thresholds. Our studies establish 
the utility of using AlphaScreen and purified protein pairs to establish and quantify disruption of 
protein-protein interactions. Our results demonstrate previously unrecognized antinociceptive 
efficacy of ZL006 and establish, using two small molecules, a broad application for PSD95-nNOS 
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inhibitors in treating neuropathic and inflammatory pain. Collectively, our results demonstrate that 
disrupting PSD95-nNOS protein-protein interactions is effective in attenuating pathological pain 
without producing unwanted side effects (i.e. motor ataxia) associated with NMDAR antagonists.
1. Introduction
Chronic pain is a devastating clinical problem resulting from nerve injury, disease states 
(e.g. diabetes or cancer) or toxic challenges. It is the most common cause of long-term 
disability, and fewer than 50% of patients receive adequate pain relief (Steglitz et al., 2012). 
Alterations in the properties of peripheral nerves by inflammation-associated changes in the 
chemical environment of the nerve fiber has been implicated in peripheral sensitization 
(Basbaum et al., 2009). In addition to peripheral mechanisms, central sensitization, a process 
which establishes hyperexcitability in the central nervous system (CNS), leads to enhanced 
processing of nociceptive messages, thus contributing to both the development and 
maintenance of chronic pain (Basbaum et al., 2009). One of the mechanisms involved in 
central sensitization is through excessive glutamatergic signaling and overactivation of the 
N-methyl-D-aspartate receptor (NMDAR) (Latremoliere and Woolf, 2009; South et al., 
2003; Woolf, 1983). Overactivation of NMDARs leads to increased calcium influx in the 
postsynaptic cell and, consequently, increases downstream signaling events critical for the 
development and maintenance of chronic pain (Latremoliere and Woolf, 2009). NMDAR 
antagonists (e.g. ketamine, MK-801, and memantine) produce antinociceptive efficacy in 
various animal pain models (Zhou et al., 2011); however, direct antagonism of NMDAR 
produces adverse pharmacological effects (e.g. motor impairment, memory impairment, 
dissociative effects) due to the broad involvement of NMDAR signaling in numerous 
physiological functions (Zhou et al., 2011).
We hypothesized that disrupting protein-protein interactions that mediate downstream 
signaling events critical for pronociceptive NMDAR activation may suppress pain without 
triggering unwanted side effects mediated by direct antagonism of NMDAR (Florio et al., 
2009). NMDAR activation leads to production of nitric oxide (NO), which, when produced 
in excess, is implicated in pathological processes including inflammation and pain (Miclescu 
and Gordh, 2009). The production of NO is linked to NMDAR activation through neuronal 
nitric oxide synthase (nNOS), an enzyme which is tethered to NMDAR by the scaffolding 
protein postsynaptic density 95 kDA (PSD95) (Christopherson et al., 1999; Luo and Zhu, 
2011; Sattler et al., 1999). This NMDAR-PSD95-nNOS complex is required for NMDAR 
mediated NO production and has thus been implicated in neurological diseases and neuronal 
excitotoxicity (Courtney et al., 2014; Li et al., 2013; Toro and Deakin, 2005). IC87201 (see 
Figure 1), the first small molecule disruptor of PSD95-nNOS interaction, produces 
antinociceptive efficacy following intrathecal administration in a manner mimicked by the 
fusion protein TAT-nNOS (Florio et al., 2009). ZL006 (see Figure 1) is a second small 
molecule disruptor of PSD95-nNOS interaction that shows therapeutic efficacy in models of 
stroke and depression (Doucet et al., 2013; Zhou et al., 2010). Whether ZL006 produces 
antinociceptive efficacy in models of pathological pain remains unknown. Disruption of the 
NMDAR-PSD95 complex with a peptide inhibitor, TAT-NR2B9c, also produces 
antinociception in a model of neuropathic pain induced by traumatic nerve injury (D'Mello 
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et al., 2011). These observations provide evidence that targeting the NMDAR-PSD95-nNOS 
complex downstream of NMDAR signaling pathway may be effective in blocking the 
NMDAR triggered central sensitization. Thus the PSD95-nNOS protein-protein interface 
represents a potential target for treating pain and other disease states involving aberrant 
NMDAR signaling.
ZL006 inhibits glutamate-induced cell death and glutamate-induced increases in nNOS-
PSD95 protein complex in primary neuronal cells (Zhou et al, 2010). However, it is unclear 
whether these effects occur through direct disruption of the PSD95-nNOS complex because 
there is no evidence that ZL006 inhibits this complex in vitro. We, therefore, examined the 
ability of small molecule inhibitors ZL006 and IC87201 to disrupt binding between purified 
PDZ domains of nNOS and PSD95 using an amplified luminescence proximity 
homogeneous assay (AlphaScreen). In addition, we characterized the effect of IC87201 and 
ZL006 on the binding of PSD95 to receptor tyrosine-protein kinase ErbB4 to assess 
specificity of these inhibitors for disrupting PSD95-nNOS protein-protein interactions. To 
characterize the cell-based efficacy of these small molecules, we evaluated whether these 
inhibitors protect cortical neurons from glutamate-induced excitotoxicity. We also 
characterized the antinociceptive efficacies of these small molecule disruptors in mouse 
models of inflammatory and neuropathic pain. Intrathecal administration of IC87201 has 
previously been shown to attenuate both NMDA-induced hyperalgesia and neuropathic pain 
induced by chronic constriction injury (CCI) (Florio et al., 2009). However, whether 
IC87201 shows antinociceptive efficacy in chronic pain models following systemic 
administration remains unknown. Here, we used two small molecule PSD95-nNOS 
inhibitors to determine whether disruption of PSD95-nNOS interactions produces broad 
spectrum antinociceptive efficacy in models of inflammatory pain induced by intraplantar 
administration of either formalin or complete Freund’s adjuvant (CFA) administration and 
neuropathic pain induced by treatment with the chemotherapeutic agent paclitaxel. Our 
studies provide evidence that ZL006 directly disrupts the PSD95-nNOS complex and 
provides the first characterization of the antinociceptive efficacy of ZL006 in pain models. 
Our studies also extend findings of Florio (2009) by evaluating efficacy of IC87201 in 
models of inflammatory pain and toxic neuropathy and by employing a systemic (i.p.) route 
of drug administration. The formalin test is a model of tonic inflammatory pain and the 
second phase of formalin-evoked nociceptive behaviors have been linked to NMDAR-
dependent central sensitization (Tjolsen et al., 1992). The CFA model is a pervasive 
inflammatory pain model which has been linked to activation of nNOS (Chen et al., 2010; 
Chu et al., 2005). Thus, these two inflammatory pain models were used, together with two 
small molecule inhibitors (i.e. IC87201 and ZL006) to ascertain whether nNOS-PSD95 
inhibitors suppress inflammatory pain. Chemotherapeutic agents, such as paclitaxel, induce 
peripheral neuropathy in mice and rats, similar to that observed in cancer patients 
undergoing chemotherapy treatment (Windebank and Grisold, 2008). Thus, we asked 
whether nNOS-PSD95 inhibitors disrupt mechanical and cold allodynia (Jaggi et al., 2011) 
induced by paclitaxel treatment in mice. We also employed the tail immersion test to assess 
whether small molecule inhibitors themselves produce analgesic effects in the absence of a 
pathological pain state. Comparisons in all studies were made with the NMDAR antagonist 
MK-801, used as a reference compound. Finally, we compared side-effect profiles of 
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PSD95-nNOS inhibitors with MK-801 using the rotarod test of motor ataxia. Our studies 
demonstrate that ZL006, like IC87201, directly disrupts the PSD95-nNOS complex and 
reveal previously unidentified anti-allodynic properties of ZL006. Our in vivo studies also 
suggest that IC87201 and ZL006 suppress a broad spectrum of pathological pain states 
without producing adverse side effects of NMDAR antagonists.
2. Materials and methods
2.1. Protein purification
Glutathione S-transferase (GST) or His-tagged proteins were expressed in E-Coli, purified 
on GST or Nickel columns respectively according to manufacturers’ instructions. 
PSD951–392 containing the PDZ domains that bind nNOS was expressed either as GST- or 
His-tagged using pGEX 4T-1 or pET-30a respectively. nNOS1–299 containing the PDZ 
domain that binds PSD95, but lacking the catalytic domain, was expressed as His-tagged.
2.2. AlphaScreen assay
AlphaScreen solution binding between nNOS and PSD95 was carried out using purified N-
terminal His-nNOS1–299 and GST-PSD951–392 proteins according to manufacturer’s 
instructions (PerkinElmer, Waltham, MA). Briefly, purified His-nNOS and GST-PSD95 
proteins were incubated for 1 h at room temperature (RT), with gentle shaking. AlphaScreen 
Ni Chelate Acceptor beads (final 20 µg/ml) and AlphaScreen Glutathione Donor beads (or 
Streptavidin donor beads for biotinylated ErbB4) (final 20 µg/ml) were sequentially added, 
with 1 h incubation for each addition. The reaction was carried out in 20–40 µl final volume 
in 96-well ½ area plates in 1X PBS, 0.1% BSA and 0.05% Tween-20. Plates were read on 
an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA) equipped with 
AlphaScreen optical detection module. 50% binding (or Kd) between His-nNOS and GST-
PSD95 was determined by titrating both proteins (0–350 nM). To test disruption of the 
protein-protein complex by small molecule inhibitors, the reaction was carried out using 
concentrations of His-nNOS and GST-PSD95 at 50% maximum binding. Inhibitors or 
vehicle (containing equivalent amount of DMSO) were added to the proteins at the 
beginning of the experiments. All the compounds used in this experiment were prepared as 
20 mM stocks dissolved in DMSO and subsequent dilutions were further made from this 
stock. Control experiments testing the ability of the small molecule inhibitors in disrupting 
bead interactions were used with recombinant GST-His tag (GenWay Biotech Inc, CA).
2.3. Embryonic cortical neuron culture
Cortical tissue from E18-E19 Sprague-Dawley rat pups was harvested according to 
approved IACUC guidelines as previously described (Ashpole and Hudmon, 2011; Hudmon 
et al., 2005). Pelleted cortical cells were resuspended in neuronal growth media (Neurobasal 
media containing 2% NuSerum (BD Biosciences, San Jose, CA), 2% NS21 (Chen et al., 
2008) and penicillin (10 units/mL), streptomycin (10 µg/mL), and L-glutamine (29.2µg/mL) 
at a density of 2.5 million cells/mL and seeded on poly-D-lysine (50 µg/mL) coated 15mm 
coverslips (German glass Number 0). Forty-eight hours after plating, cultures were treated 
with 5-fluor-2’-deoxyuridine (1.5 µg/mL) and uridine (3.5 µg/mL).
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2.4. Excitotoxic Stimulation
Neurons (7–8 DIV) were pretreated with the small molecule inhibitors IC87201 (10 µM), 
ZL006 (10 µM), the NMDAR antagonist MK-801 (20 µM) or vehicle for 20 min at 37°C 
and subsequently stimulated with 200 µM glutamate/20 µM glycine for 1 h at 37 °C 
(Ashpole and Hudmon, 2011). Following treatment, stimulation media was washed out with 
fresh neuronal growth media and the neurons were incubated for 24 h until analysis.
2.5. Cell death assay
Twenty-four hours following excitotoxic stimulation, the coverslips were washed in PBS 
and stained using Live/Dead Cytotoxicity/Viability kit per manufacturer’s recommendation 
(Molecular Probes, Eugene, OR). Following staining, the coverslips were washed in PBS 
and immediately imaged on Nikon Ti-E inverted microscope (100X magnification). Each 
coverslip was imaged in three different fields using a Texas Red filter to detect cytotoxic 
cells and a FITC filter to detect viable cells. Cells were quantified using the automated 
counting software Nikon Elements 3.0.
2.6. Animals and housing conditions
Adult C57BL/6J male mice (Jackson Laboratory, Bar Harbor, ME), weighing 23–33g were 
used in these experiments. Animals were maintained in a temperature-controlled facility (73 
±2°F, 45% humidity, 12-hour light/dark cycle) with food and water ad libitum. All 
experimental procedures were approved by Bloomington Institutional Animal Care and Use 
Committee of Indiana University and followed guidelines of the International Association 
for the Study of Pain.
2.7. Drugs and chemicals
ZL006 and IC87201 were synthesized for our studies by the METACyt facility (Indiana 
University, Bloomington) and subsequently in the laboratory of Dr. Ganesh Thakur, (by 
P.M.K) at Northeastern University Center for Drug Discovery (Boston, MA). MK-801 was 
purchased from Sigma Aldrich (St. Louis, MO). All drugs were dissolved in 3% DMSO, 
1:1:18 of emulphor (Alkamuls EL 620L; Solvay): ethanol (Sigma-Aldrich): 0.9% NaCl 
(Aquilite System; Hospira, Inc, Lake Forest, IL).
2.8. Formalin test
Animals were injected intraperitoneally (i.p.) with IC87201 (4 or 10 mg/kg, i.p.), ZL006 (4 
or 10 mg/kg, i.p.), MK-801 (0.1 mg/kg, i.p.) or vehicle thirty minutes prior to intraplantar 
(i.pl.) injection of formalin. Animals were placed in an elevated clear observation chamber 
immediately after injection. Thirty minutes after injection, animals were injected (10 µl) 
unilaterally into the plantar surface of the right hind paw with 2% formalin (37% 
formaldehyde diluted in 0.9% NaCl). Resulting nociceptive behaviors were scored for forty 
minutes immediately following formalin injection. Composite pain scores were calculated 
for every 5 minute bin for a total duration of 40 min using the following scoring criteria: no 
behavior was scored 0, lifting was scored 1, and shaking/biting/flinching was scored as 2. 
Pain behavior was separated into the early phase (phase 1) and late phase (phase 2A and 
phase 2B) of pain behavior, similar to that described previously (Malmberg and Yaksh, 
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1992; Tjolsen et al., 1992).The area under the curve of pain behavior was calculated for 
Phase 1 (0–10 min), phase 2A (10–20 min) and phase 2B (20–40 min) for each subject and 
subjected to statistical analysis.
2.9. Paclitaxel-induced neuropathy
Paclitaxel (Tecoland Corporation, Irvine, CA) was dissolved in a vehicle consisting of a 
1:1:4 ratio of cremophor EL (Sigma-Aldrich, St. Louis, MO)/ethanol (Sigma-Aldrich) saline 
(Aquilite System; Hospira, Inc, Lake Forest, IL). Animals were injected with either the 
cremophor-vehicle or paclitaxel (4 mg/kg, i.p.) on day 0, 2, 4, and 6 following initiation of 
paclitaxel dosing (16 mg/kg i.p. cumulative dose). Baseline (day 0) responding to 
mechanical stimulation was assessed before initiation of paclitaxel (or vehicle) dosing. 
Responsiveness to mechanical stimulation was also assessed during development and 
maintenance phases of paclitaxel-induced hypersensitivity on days 4, 7, 11 and 15.
2.10. Dose response of PSD95-nNOS inhibitors in paclitaxel induced neuropathy model
When paclitaxel induced neuropathy was stable (i.e. beginning on day 16 post initiation of 
paclitaxel dosing), mice were injected with IC87201 (0.1, 0.3, 1, 3, 10, and 30 mg/kg i.p, 
respectively), ZL006 (0.1, 0.3, 1, 3, 10, and 30 mg/kg i.p, respectively) or vehicle every 
three days using a within subjects dosing paradigm. Pre-injection baselines were measured 
prior to each injection day, ensuring that the mechanical and cold responsiveness returned to 
baseline, without any carry over effects, prior to dose escalation. Responsiveness to 
mechanical and cold stimulation was assessed 30 min after drug or vehicle injection to 
calculate ED50s for suppressing paclitaxel-induced mechanical and cold allodynia.
2.11. Time course of suppression of paclitaxel-induced allodynia by PSD95-nNOS 
inhibitors and comparison to MK-801
In a separate study, we established the time course of anti-allodynic efficacy of PSD95-
nNOS inhibitors on paclitaxel-induced mechanical allodynia using the maximally effective 
doses of PSD95-nNOS disruptors identified in the dose response study described above. 
Mice were treated with either paclitaxel or cremophor-vehicle as described above. On day 
16 following initiation of paclitaxel (or cremophor vehicle) dosing, mice received a single 
i.p. injection of IC87201 (10 mg/kg, i.p.), ZL006 (10 mg/kg, i.p.), MK-801 (0.1 mg/kg, i.p.) 
or vehicle. Responsiveness to mechanical stimulation was assessed before pharmacological 
manipulations (pre drug post paclitaxel baseline) and then reassessed at 30, 90, and 150 
minutes after drug injection.
2.12. Complete Freund’s adjuvant (CFA) induced inflammatory pain
Mice received a single intraplantar (20 µl i.pl.) injection of complete Freund’s adjuvant 
(CFA; Sigma-Aldrich, St. Louis, MO) diluted with saline in a 1:1 ratio in the right hind paw. 
Mechanical thresholds that elicited paw withdrawal were assessed with an electronic von 
Frey anesthesiometer (IITC Life Science, Woodland Hills, CA). Thresholds were assessed 
prior to CFA injection (baseline) and 48 hours after CFA administration (pre drug baseline). 
Mice were then treated with IC87201 (10 mg/kg, i.p), ZL006 (10 mg/kg, i.p), MK-801 (0.1 
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mg/kg, i.p) or vehicle and responsiveness to mechanical stimulation was reassessed again at 
30, 90, and 150 minutes after pharmacological manipulations.
2.13. Assessment of mechanical allodynia
Withdrawal thresholds (g) to mechanical stimulation were measured in duplicate for each 
paw using an electronic von Frey anesthesiometer supplied with a 90-g semi-flexible probe 
(IITC Life Science, Woodland Hills, CA) as described previously (Deng et al., 2015; 
Guindon et al., 2013).
2.14. Assessment of cold allodynia
Cold allodynia was assessed by applying acetone (Sigma Aldrich, St. Louis, MO) to the 
plantar surface of the hind paw. Time spent reacting to acetone stimulation was measured in 
triplicate for each paw (Deng et al., 2015; Ward et al., 2011).
2.15. Rota-rod test
Motor performance was assessed using an accelerating Rota-rod (IITC Life Science) (4–40 
rpm with cutoff time of 300 sec). Mice were trained for two days and on the third day, the 
baseline descent latency was measured. On the fourth day, the mice were injected with 
IC87201 (10 mg/kg, i.p.), ZL006 (10 mg/kg, i.p.), MK-801 (1 mg/kg, i.p.) or vehicle. Thirty 
minutes after the injection, the mice were placed on the accelerating rod and the latency for 
the animals to stay on the rod was recorded. On the baseline and post-drug test day, the 
animal must pass a criterion in order to advance to assessment of drug effects. Animals that 
did not pass criteria (i.e. ability to walk on rotating drum for 30 sec) did not receive 
pharmacological manipulations.
2.16. Effects of supramaximal doses in tail-flick test of analgesia and rota-rod test of motor 
ataxia
To ascertain whether PSD95-nNOS inhibitors (i.p.) produce antinociception in the absence 
of pathological pain, we evaluated PSD95-nNOS inhibitors in the tail-flick test at doses that 
were three times higher than the maximally effective anti-allodynic doses identified in our 
studies. We also evaluated the possible side effect profile of these supra-maximal doses in 
the rota-rod test using the same animals. Mice were trained in the rota rod test on two days 
prior to establishment of the tail flick baseline. Baseline tail flick latency was measured by 
immersing one half to two thirds of the tail into 53–54°C of warm water. The latency for an 
animal to remove its tail from the water was measured three times prior to pharmacological 
manipulations. Mice received IC87201 (30 mg/kg, i.p), ZL006 (30 mg/kg, i.p), MK-801 (0.3 
mg/kg, i.p) or vehicle. Tail flick latency was measured again 30 min after drug or vehicle 
administration. Immediately after determination of post-injection tail-flick latencies, the 
latency for animals to fall of the rota-rod was again recorded in duplicate.
2.17. Statistical Analysis and ED50 calculation
IC50 or EC50 values in AlphaScreen were calculated by non-linear regression analysis using 
the equation of a sigmoid concentration-response curve (GraphPad Prism). The following 
formula was used to calculate %MPE: (Post paclitaxel post drug response - Post paclitaxel 
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pre drug response)/(Pre paclitaxel baseline - Post paclitaxel pre drug response) × 100. ED50 
was then determined by the equation of non-linear regression for log (inhibition) versus 
response curve (GraphPad Prism). Impact of PSD95-nNOS inhibitors and MK-801 on 
glutamate-induced cell death was analyzed by one way ANOVA followed by Bonferroni 
post hoc tests. In vivo data were analyzed by repeated measures and one-way ANOVA, as 
appropriate. The area under the curve (AUC) of pain behavior was calculated for phase 1, 
phase 2A and phase 2B and ANOVA was performed on each phase separately. Analysis of 
variance for repeated measures was used to determine the time course of drug effects. One-
way ANOVA was then used to identify the time points during which group differences 
attributable to significant interactions were observed. Bonferroni was used for post hoc tests. 
All statistical analyses were performed using IBM-SPSS Statistics version 22.0 (SPSS inc., 
an IBM company, Chicago, IL, USA). p<0.05 was considered statistically significant.
3. Results
3.1. Small molecules, IC87201 and ZL006, inhibit PSD95-nNOS protein-protein interactions 
in vitro
IC87201 was first identified from a high-throughput screen as a PSD95-nNOS inhibitor 
using an in vitro plate binding assay (Florio et al., 2009), but in vitro data documenting 
disruption of PSD95-nNOS binding by ZL006 has never been reported. We, therefore, 
developed in vitro protein-protein interaction solution binding assays using AlphaScreen to 
detect the complex of the PDZ domains of PSD95 and nNOS and disruption by small 
molecules (Figure 2). N-terminal His-nNOS1–299 and GST-PSD951–392 were bound to Ni-
chelate acceptor beads and Glutathione-donor beads respectively. Saturation binding 
between His-nNOS1–299 and GST-PSD951–392 using increasing concentrations (0–350 nM) 
of both proteins showed that the proteins bind with an EC50 of 30 nM in an AlphaScreen 
assay (Figure 2A; consistent with data published previously in (Harris et al., 2001; Tochio et 
al., 2000)). nNOS1–130 without any tag competed effectively with nNOS-PSD95 interaction 
with IC50 of 30 nM (data not shown) similar to Kd of the binding. Small molecule inhibitors 
IC87201 and ZL006 inhibited the interaction between GST-PSD951–392 and His-nNOS1–299 
(Figure 2B) with IC50 of 23.94 ± 9.89 µM (n = 7) and 12.88 ± 4.14 µM (n = 7), respectively. 
As a control, we used a protein containing both GST-His tags to measure interaction 
between Ni-chelate acceptor and Glutathione-donor beads. IC87201 and ZL006 did not 
inhibit the acceptor-donor bead interaction in an AlphaScreen binding assay using this 
recombinant GST-His control protein (data not shown).
3.2. IC87201 and ZL006 do not disrupt ErbB4-PSD95 interactions
To investigate whether these small molecule PSD95-nNOS inhibitors disrupt other PDZ-
PDZ protein interactions, we characterized related protein-protein interactions involving 
PDZ domains of nNOS and ErbB4. The PDZ2 domain of PSD95 interacts with the receptor 
tyrosine-protein kinase ErbB4 (Garcia et al., 2000; Huang et al., 2000) In our AlphaScreen 
binding assay, the biotinylated C-terminal tail of ErbB4 (amino acid1289–1308) interacts 
with a His fusion protein containing the PDZ1–3 domain of PSD95 with an apparent affinity 
of 10 nM (Figure 2C). IC87201 and ZL006 (up to 150 µM) had no effect on the interaction 
between ErbB4 and PSD95 (n = 2; Figure 2D).
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3.3. Glutamate-induced excitotoxicity is antagonized by IC87201 and ZL006
The ability of the PSD95-nNOS inhibitors to protect neurons from excitotoxic death was 
examined in cultured cortical neurons subjected to glutamate (200 µM)/glycine (20 µM) for 
1 h. Glutamate/glycine induces cell death in primary cortical neurons [p < 0.0001] pre-
treated with vehicle relative to the control level (no glu/gly). However, glutamate-induced 
neuronal death was attenuated in cortical neurons pretreated with either IC87201 (10 µM), 
ZL006 (10 µM), or the NMDAR antagonist MK-801 (20 µM) [p < 0.001 for all 
comparisons] relative to glu/gly treatment in neurons pre-treated with vehicle (Figure 3). 
Cell death in IC87201, ZL006, and MK-801 conditions did not differ from each other and 
was normalized relative to control levels (Figure 3).
3.4. Small molecule PSD95-nNOS inhibitors attenuate formalin-induced pain behaviors
Intraplantar formalin (2% in10 µl) induced time dependent changes in pain related behaviors 
in all studies [p < 0.001 ANOVA]. The high dose of IC87201 (10 mg/kg i.p.) suppressed 
composite pain scores relative to vehicle [F1,13 = 7.727, p < 0.001] and these effects were 
time dependent [F8,144 = 2.775, p = 0.008] (Figure 4A). The low dose of IC87201 did not 
reliably suppress formalin-induced pain behavior, although antinociceptive effects of the 
high and low doses did not differ over the entire observation interval (Figure 4A). The high 
dose of IC87201 preferentially suppressed the AUC of formalin-induced pain behavior 
relative to vehicle during phase 2A [p < 0.05, bonferroni] but not during phase 2B [p = 
0.307] or phase 1 [p = 0.94] (Figure 4B).
ZL006 attenuated formalin-induced pain behavior [F2,17 = 13.067, p < 0.0004, ANOVA] 
relative to vehicle treatment and these effects were time dependent [F16,136 = 2.877, p < 
0.0005] (Figure 4C). Both doses of ZL006 suppressed phase 1 pain behavior in comparison 
to the vehicle-treated group (Figure 4C) [p < 0.01, at 4 and 10 mg/kg, bonferroni]. Post hoc 
analysis revealed that the high dose of ZL006 suppressed formalin-evoked pain behavior 
from 15–20 min [p < 0.01 for each comparison, bonferroni] following injection whereas the 
low dose suppressed pain at 15 min only [p < 0.05, bonferroni]. Similarly, both doses of 
ZL006 reduced the AUC of pain behavior relative to vehicle treatment during both phase 
1[p < 0.01 for both doses, bonferroni] and phase 2A [p < 0.05 for 4 mg/kg; p < 0.01 for 10 
mg/kg] but not phase 2B (Figure 4D).
We compared effects of efficacious doses of PSD95-nNOS inhibitors with the NMDAR 
antagonist MK-801 in the formalin test. The experimental treatments suppressed composite 
pain scores [F3,23 = 12.251, p < 0.00006] and these effects were time dependent [F3,21 = 
5.912, p < 0.005] (Figure 4E). Post hoc analyses revealed that both ZL006 and MK-801 
suppressed composite pain scores during phase 1 (5 min post formalin injection) and from 
15–20 min post formalin (p < 0.001), whereas antinociceptive effects of IC87201 were 
reliable at 20 min only (p = 0.002) (Figure 4E). Both MK-801 and ZL006 reduced AUC of 
pain behavior during phase 1 and phase 2A relative to the vehicle group (Figure 4F) [phase 
1: p < 0.01 ZL006, p < 0.001 MK-801; phase 2A: p < 0.001 ZL006, p < 0.001 MK-801, 
bonferroni], whereas IC87201 reduced AUC of pain behavior during phase 2A only (Figure 
4F) [p < 0.05, bonferroni] without reliably altering pain behavior during phase 1 or phase 2b 
[p > 0.064 for each comparison].
Lee et al. Page 9
Neuropharmacology. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
3.5. Small molecule PSD95-nNOS inhibitors suppress mechanical allodynia induced by 
complete Freund’s adjuvant
The baseline mechanical threshold did not differ between the two hind paws prior to CFA 
injection [p = 0.305, independent sample t-test]. CFA decreased mechanical paw withdrawal 
thresholds in the paw ipsilateral [p < 0.005, paired sample t-test] but not contralateral to 
CFA injection. The small molecule inhibitors elevated paw withdrawal thresholds relative to 
pre-treatment thresholds [F3,60 = 20.535; p = 0.017] (Figure 5A).
Both IC87201 [p < 0.003, bonferroni] and ZL006 [p < 0.002, bonferroni], at doses of 10 
mg/kg i.p., suppressed mechanical allodynia starting at 30 min post injection relative to 
vehicle. Both small molecules normalized mechanical paw withdrawal thresholds to pre-
CFA levels [p = 0.216 at 30 min IC87201; p = 0.283 at 30 min ZL006 two tailed paired 
sample t-test] ] (Figure 5A). Similarly, MK-801 (0.1 mg/kg, i.p.) suppressed CFA-induced 
mechanical allodynia relative to vehicle [p < 0.009, 30 min post injection; bonferroni] and 
normalized paw withdrawal thresholds to pre-CFA baseline levels [p = 0.283 at 30 min, 2 
tailed paired sample t-test] (Figure 5A). However, anti-allodynic efficacy was no longer 
present 90 min following any treatment [p = 0.962, MK-801 bonferroni; p = 1.00, IC87201; 
p = 1.00, ZL006]. Mechanical paw withdrawal thresholds did not differ in the paw 
contralateral to CFA injection in any group [F3,20 = 2.549, p = 0.085] or at any time point 
[F9,60 = 0.524, p = 0.852] (Figure 5B).
3.6. Dose response of small molecule inhibitors in paclitaxel-induced neuropathy pain 
model
Paclitaxel produced mechanical and cold allodynia relative to pre-paclitaxel baseline 
responsiveness [p < 0.007 mechanical; p < 0.002 cold, paired sample t-test] (Figure 6A–F). 
Both mechanical and cold allodynia were assessed prior to every pharmacological treatment 
in mice used to calculate within subjects dose response curves; no residual drug effects were 
observed in either mechanical [F2,15 = 0.774, p = 0.479; Figure 6A] or cold [F2,15 = 0.17, p 
= 0.846; Figure 6B] responsiveness during the maintenance phase of paclixel-induced 
allodynia, assessed prior to subsequent dose escalations.
IC87201 and ZL006 attenuated established paclitaxel-induced mechanical allodynia [F2,15 
=12.562; p = 0.001] relative to vehicle treatment [p < 0.04, bonferroni] at doses (i.p.) of 3 
mg/kg [p = 0.033 IC87201; p = 0.006 ZL006, bonferroni], 10 mg/kg [p = 0.001 IC87201; p 
< 0.001 ZL006, bonferroni] and 30 mg/kg [p < 0.001 IC87201; p < 0.001 ZL006, 
bonferroni] (Figure 6C). Post injection mechanical paw withdrawal thresholds were also 
normalized to baseline (pre-paclitaxel) thresholds at doses of 3 mg/kg [p = 0.245 IC87201; p 
= 0.273 ZL006, paired sample t-test] and 10 mg/kg i.p. [p = 0.634 IC87201; p = 0.975 
ZL006, paired sample t-test] (Figure 6C). Similarly, IC87201 and ZL006 also attenuated 
cold allodynia provoked by paclitaxel treatment at doses of 10 mg/kg [p = 0.002 IC87201; p 
< 0.001 ZL006, bonferroni] and 30 mg/kg i.p. [p = 0.004 IC87201; p = 0.002 ZL006, 
bonferroni] relative to vehicle treatment (Figure 6D). Responsiveness to cold was 
normalized to baseline pre-paclitaxel responsiveness at a dose of 10 mg/kg for ZL006 [p = 
0.38, paired sample t-test] (Figure 6D). The dose response relationship of IC87201 and 
ZL006 in suppressing allodynia was further plotted as % maximal possible effect (%MPE) 
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and ED50 were determined with non-linear regression curves. The ED50 for suppression of 
mechanical allodynia was 2.47 ± 1.3 mg/kg, i.p. for IC87201 and 0.93 ± 0.43 mg/kg, i.p. for 
ZL006 (Figure 6E). The ED50 for suppression of cold allodynia was 1.6 ± 0.33 mg/kg, i.p. 
for IC87201 and 3.7 ± 0.54 mg/kg, i.p. for ZL006 (Figure 6F). The ED50 determined for 
suppression of mechanical allodynia did not differ between the two small molecule 
inhibitors [p = 0.266]. However, the ED50 for suppression of cold allodynia was lower for 
ZL006 compared to IC87201 [p < 0.002; independent sample t-test, two tailed].
3.7. Time course of suppression of paclitaxel-induced allodynia induced by nNOS-PSD95 
inhibitors and comparison with MK-801
We evaluated the time course of anti-allodynic efficacy of maximally effective doses of 
PSD95-nNOS inhibitors in mice treated with either paclitaxel or its cremophor-based 
vehicle. There were no differences between groups in mechanical paw withdrawal 
thresholds prior to administration of paclitaxel or cremophor vehicle [p = 0.589, one way 
anova]. Paclitaxel decreased mechanical paw withdrawal thresholds [F1,46 = 58.702; p < 
0.001] relative to the cremophor-treated group [p < 0.006, one-way anova] prior to drug 
treatments, consistent with the development of mechanical allodynia (Figure 7A). 
Mechanical allodynia was maintained from day 4 to day 15 in paclitaxel-treated group 
relative to day 0 pre-paclitaxel baseline responding [F4,184 = 5.94, p < 0.0002] prior to drug 
manipulations (Figure 6A).
Small molecule PSD95-nNOS inhibitors (10 mg/kg i.p.) attenuated paclitaxel-induced 
mechanical allodynia [F3,20 = 4.46; p < 0.02] relative to vehicle [p < 0.05, bonferroni] and 
pre-injection levels [F9,60 = 2.305; p = 0.036] (Figure 7B). This pattern of suppression was 
similar to that produced by the NMDAR antagonist MK-801. MK-801 (0.1 mg/kg i.p.) 
similarly suppressed paclitaxel-induced mechanical allodynia relative to vehicle [p < 0.05, 
bonferroni] from 30 to 90 min post injection (Figure 7B) and normalized paw withdrawal 
thresholds to pre-paclitaxel baseline levels [p = 0.662 at 30 min; p = 0.103 at 90 min, 2 
tailed paired sample t-test]. Similarly, both IC87201 [p < 0.02, bonferroni] and ZL006 [p < 
0.05, bonferroni] suppressed mechanical allodynia starting at 90 min post injection relative 
to vehicle and normalized thresholds to pre-paclitaxel levels [p = 0.215 at 90 min IC87201; 
p = 0.15 at 90 min ZL006 two tailed paired sample t-test] (Figure 6B). Anti-allodynic 
efficacy was no longer present 150 min following injection after any treatment [p > 0.299]. 
Moreover, in cremophor vehicle-treated mice, MK-801, IC87201 and ZL006 did not alter 
mechanical withdrawal thresholds [F3,20 = 0.437, p = 0.729] or produce antinociception at 
any time point [F12,80 = 0.623, p = 0.817] (Figure 7C).
3.8. Small molecule PSD95-nNOS inhibitors do not produce motor ataxia at efficacious 
doses
Neither IC87201 nor ZL006, administered at anti-allodynic doses (10 mg/kg, i.p), produced 
motor ataxia in the rota-rod test (Figure 8) [F4,31 = 2.124, p = 0.101]. A high dose (1 mg/kg 
i.p.) but not the low dose (0.1 mg/kg i.p.) of MK-801 impaired motor coordination relative 
to the vehicle-treated group (Figure 8) [p < 0.003, bonferroni].
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3.9. Supramaximal doses of small molecule PSD95-nNOS inhibitors do not produce 
analgesia in tail-flick test or motor ataxia
Supra-maximal doses (30 mg/kg i.p.) of IC87201 and ZL006, administered at three times the 
maximal anti-allodynic dose, did not alter tail-flick latencies in otherwise naïve animals 
[F3,20 = 1.326, p = 0.294] (Figure 9A). MK-801 (0.3 mg/kg i.p) produced hyperalgesia 
relative to the vehicle group under identical conditions [p = 0.035, bonferroni] (Figure 9A). 
Motor ataxia was not observed in the rota-rod test in the same mice treated with either 
IC87201 or ZL006 (30 mg/kg, i.p.) (Figure 9B) [F3,20 = 2.721, p = 0.072]. Motor 
coordination was significantly impaired relative to vehicle in MK801-treated mice (0.3 
mg/kg i.p.) under analogous conditions [p < 0.001, bonferroni].
4. Discussion
Our studies provide evidence that two small molecule protein-protein interaction inhibitors, 
IC87201 and ZL006, disrupt binding of purified nNOS and PSD95 proteins in vitro, protect 
against glutamate-induced excitotoxicity in cortical neurons and produce antinociceptive 
effects similar to the NMDAR antagonist MK-801. Strikingly, motor ataxic effects 
associated with NMDAR blockade were absent at therapeutically efficacious doses of 
nNOS-PSD95 inhibitors and doses three times higher than the maximal anti-allodynic doses 
of these agents. NMDAR activation induces NO production by nNOS; this signaling cascade 
is critically involved in central sensitization, a process which underlies the development and 
maintenance of pathological pain (Latremoliere and Woolf, 2009). PSD95 tethers nNOS to 
NMDAR, serving a key linking NO production to NMDAR activation. IC87201, the first in 
class PSD95-nNOS small molecule inhibitor disrupted PSD95-nNOS interaction in a plate 
binding assay and attenuated the NMDA-induced increases in cGMP production in primary 
hippocampal neurons in vitro (Florio et al., 2009). These findings suggest that NO 
production downstream of NMDAR activation is inhibited by PSD95-nNOS disruption with 
IC87201. Similarly, ZL006, a related chemical analog of IC87201 identified by Zhou and 
colleagues, was shown to reduce PSD95-nNOS association in neurons treated with Glu-Gly 
(Zhou et al, 2010), although it is unclear whether these effects could be attributed to direct 
disruption of PSD95-nNOS binding. In this latter study, ZL006 also inhibited NMDAR-
dependent NO synthesis (Zhou et al, 2010). The above studies suggest that disruption of 
PSD95-nNOS interactions reduces NMDAR activation-induced NO production. We, 
therefore, evaluated whether disruption of PSD95-nNOS protein-protein interactions 
represents a potential therapeutic strategy for treating inflammatory and neuropathic pain. 
IC87201 has been shown to attenuate NMDA-induced heat hyperalgesia in mice and 
mechanical allodynia induced by chronic constriction injury (CCI) in rats following 
intrathecal administration (Florio et al, 2009). Whether the in vivo actions of IC87201 are 
mediated by PSD95-nNOS disruption or other as yet uncharacterized effects of this 
molecule remain unknown. We, therefore, chose to evaluate whether ZL006 and IC87201 
show a similar pattern of efficacy in disrupting both PSD95-nNOS binding and glutamate-
induced cell death in vitro and in producing antinociception in vivo.
We used AlphaScreen technology to evaluate the ability of IC87201 and ZL006 to disrupt 
PSD95-nNOS interactions through a direct mechanism in vitro. Our studies, using pairs of 
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purified proteins, demonstrate beyond doubt that IC87201 and ZL006 disrupt PSD95-nNOS 
interactions. These observations are consistent with the hypothesis that these small molecule 
act through a direct mechanism to inhibit association of nNOS with PSD95. The 
observations from our biochemical assay are important because feedforward/feedback loops 
in more complex cellular systems such as neuronal cells could influence PSD95-nNOS 
interactions through indirect mechanisms. Our studies are consistent with prior conclusions 
of the potential mechanisms of action of these small molecules (Florio et al, 2009; Zhou et al 
2010) using different methodologies. The specificity of IC87201 is suggested by the failure 
of IC87201 to disrupt interactions between PSD95-Cypin in vitro (cytosolic regulator of 
PSD95 postsynaptic targeting) (Florio et al, 2009). ZL006 disrupts PSD95-nNOS co-
immunoprecipitation in ischemic cortexes but not co-immunoprecipitation of PSD95-
SynGAP (synaptic GTPase activating protein) or nNOS-CAPON (carboxyl-terminal PDZ 
ligand of nNOS) (Zhou et al, 2010). To assess specificity of the presumed biochemical 
mechanism of these inhibitors, we tested the ability of our small molecules to disrupt 
another PSD95-interacting partner, ErbB4, because PDZ1 and PDZ2 of PSD95 are known to 
interact with ErbB4 (Garcia et al., 2000; Huang et al., 2000). Our results show that both 
IC87201 and ZL006 specifically disrupt PSD95-nNOS through a direct mechanism but do 
not disrupt PSD95-ErbB4 interactions.
ZL006 pretreatment inhibits NMDAR-dependent excitotoxicity induced by glutamate-
glycine treatment (Zhou et al., 2010). Similarly, we pre-treated cortical neuronal cells with 
either IC87201 or ZL006 (at 10 µM concentrations) and challenged the cells with glutamate/
glycine. Our results verify that small molecule inhibitors protect against NMDAR 
activation-mediated cell death, consistent with the previous findings using ZL006 (Zhou et 
al., 2010). Note that the concentrations used in the cell death assay reaches nearly complete 
protection, however, the concentrations used in this study is lower than the IC50 determined 
with AlphaScreen. This inconsistency could be explained by the fact that in biochemical 
binding assays employing purified proteins more proteins needed to be disrupted in order to 
calculate a 50% inhibition compared to the native state. In the cell-based assay, it is possible 
that protective effects can be observed with smaller magnitudes of disruption of the protein 
complex. Collectively, the data above extend the results of our AlphaScreen binding assays 
by demonstrating that both IC87201 and ZL006 penetrate cells to disrupt glutamate-
dependent signaling and also suggest that disruption of nNOS interaction with PSD95 
contributes to excitotoxic cell death. Therefore, disrupting PSD95-nNOS interactions 
protects neurons from excitotoxic injury. In addition, ZL006 did not inhibit excitatory 
postsynaptic currents of NMDAR (Zhou et al., 2010); therefore, attenuation of excitotoxicity 
was not likely due to direct inhibition of Ca2+ entry. IC87201 also attenuates NMDA-
induced heat hyperalgesia (Florio et al, 2009), suggesting that NMDAR-activated 
downstream signaling is disrupted in vivo to produce antinociception.
Our studies demonstrate, for the first time, that the small molecule PSD95-nNOS inhibitor 
ZL006 produces antinociception in animal pain models. We also asked whether IC87201 
and ZL006 exhibit broad spectrum analgesic efficacy in models of inflammatory and 
neuropathic pain. Thus, it is noteworthy that both small molecules showed antinociceptive 
efficacy in inflammatory and neuropathic pain models, including a model of chemotherapy-
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induced neuropathy induced by paclitaxel. Thus, anti-allodynic efficacy of IC87201 is 
observed following systemic drug administration and is not restricted to models of traumatic 
nerve injury (Florio et al, 2009). Peripheral nerve injury models such as CCI and toxic 
chemotherapy-induced neuropathy have different underlying mechanisms. Traumatic nerve 
injury induced by CCI evokes microgliosis, which is evident by microglia activation at the 
injury site (Calvo and Bennett, 2012). On the other hand, chemotherapy-induced 
neuropathic pain, such as that induced by paclitaxel, involves distal axonal injury and partial 
degeneration of the intraepidermal nerve fibers without changing microglial morphology 
and accumulation during the maintenance of allodynia (Zheng et al., 2011). Astrogliosis and 
downregulation of glial glutamate transporters GLAST and GLT-1 also contribute to 
paclitaxel-induced neuropathic pain (Zhang et al., 2012). Therefore, small molecule PSD95-
nNOS disruptors show promise for treating a broad spectrum of neuropathic pain states 
induced by traumatic nerve injury and toxic challenges.
Both IC87201 and ZL006 attenuated formalin pain behavior preferentially during phase 2A. 
Whereas phase 1 of formalin pain reflects primary afferent activation, phase 2 is specifically 
linked to central sensitization involving NMDAR activation (Tjolsen et al., 1992) but also 
involves continued activity in primary afferent fibers; this may partially explain the 
behavioral differences in 2A and 2B responding (Kaneko and Hammond, 1997). Thus, 
PSD95-nNOS disruptors may be maximally efficacious during development of central 
sensitization when MK-801 is also most efficacious. GABA activity diminishes the 
magnitude of pain behaviors in phase 2A and could possibly limit the development of 
central sensitization in the spinal cord (Kaneko and Hammond, 1997). This may also explain 
why the antinociceptive efficacy of both small molecule inhibitors is more profound in 
phase 2A compared to 2B; inhibitory effects of GABA in phase 2A are enhanced when 
NMDAR-dependent glutamate signaling is suppressed by PSD95-nNOS disruption.
Interestingly, ZL006, like MK-801, also attenuated nociceptive behaviors during phase 1, 
which may involve direct chemical activation of primary afferent fibers (Abbadie et al., 
1997). ZL006 was also a more potent antinociceptive agent in this formalin pain model 
relative to IC87201. More work is necessary to determine why IC87201 and ZL006 
produced differential effects on phase 1 of formalin pain behaviors. ZL006 also exhibited a 
lower IC50 for disrupting PSD95-nNOS binding in our biochemical AlphaScreen assay.
The CFA model is an inflammatory pain model linked to the activation of nNOS (Chen et 
al., 2010; Chu et al., 2005). Our results show that both IC87201 and ZL006 were as 
efficacious as MK-801 in attenuating CFA -induced mechanical allodynia. These small 
molecule inhibitors may abolish the CFA-induced increased nNOS activity by disrupting 
PSD95-nNOS interaction as the association of NMDAR-PSD95-nNOS is necessary for 
nNOS activation (Rameau et al., 2004).
PSD95-nNOS inhibitors did not alter basal nociceptive thresholds in the absence of 
pathological pain and also failed to produce motor ataxic effects associated with NMDAR 
antagonists. Doses of small molecule PSD95-nNOS inhibitors that suppressed mechanical 
allodynia induced by either paclitaxel or CFA and also produced antinociception in the 
formalin test did not alter mechanical thresholds in mice that did not receive paclitaxel. 
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Moreover supramaximal doses of IC87201 and ZL006 did not produce analgesia or 
hyperalgesia in the tail flick test in otherwise naïve mice. Thus, the agents normalized 
sensitization induced by inflammatory and neuropathic pain to pre-injury levels without 
producing analgesia. The tail flick assay also revealed that MK-801 produced hyperalgesia 
under these conditions, whereas IC87201 and ZL006 did not alter basal nociceptive 
thresholds. This observation is consistent with previous studies in rats demonstrating that 
acute systemic MK-801 treatment induced mechanical and heat hyperalgesia; this 
hyperalgesic effect may be associated with increased substance P (SP) and decreased 
neuropeptides enkephalin (Enk) efficiency (Al-Amin et al., 2003; Schmidt et al., 2009). 
More work is needed to determine whether small molecules themselves also fail to disturb 
the levels of these neuropeptides.
We generated dose response curves to calculate the ED50 for IC87201 and ZL006 to 
suppress mechanical and cold allodynia in the paclitaxel model. The ED50 of the small 
molecules did not differ in their ability to suppress mechanical allodynia whereas the ED50 
for ZL006 was lower than that for IC87201 for suppression of cold allodynia. It is important 
to note, however, that our studies failed to identify a systemic dose of PSD95-nNOS 
inhibitors that produced motor impairment (but see (Florio et al., 2009)). Antinociceptive 
doses of PSD95-nNOS inhibitors up to 30 mg/kg (i.p) failed to produce any observable sign 
of motor impairment, whereas profound motor ataxia was observed at a dose of 0.3 mg/kg 
i.p. of MK-801 in the rota-rod test. Thus, although the ED50 for the small molecule PSD95-
nNOS inhibitors may be higher than that observed for systemically administered MK-801 
for suppressing allodynia (e.g. ED50s: 0.15 mg/kg i.p (capsaicin model; (Amador et al., 
2001)); 0.01mg/kg i.p. (formalin model (Berrino et al., 2003)), PSD95-nNOS inhibitors 
clearly exhibit more favorable therapeutic ratios compared to NMDAR antagonists.
Antinociceptive effects of PSD95-nNOS inhibitors are not due to nonspecific disruption of 
motor function by the small molecules. The rotarod results, in conjunction with the ED50 for 
anti-allodynic efficacy determined in paclitaxel model, suggest that PSD95-nNOS small 
molecules inhibitors have a wider therapeutic window compared to MK-801 (complete 
immobility at 0.3 mg/kg i.p.). Thus, PSD95-nNOS disruptors are likely to exhibit favorable 
therapeutic ratios compared to NMDAR antagonists. Moreover, ZL006, unlike the nNOS 
inhibitor, 7-nitroindazole (7-NI), did not alter the acquisition of a spatial water maze task 
nor did it produce aggressive behaviors (Zhou et al., 2010). Thus, other side effect profiles 
(e.g. memory impairment) of NMDAR antagonists that were not measured in the present 
study may also be spared by PSD95-nNOS inhibitors.
In summary, we show that IC87201 and ZL006 specifically disrupt PSD95 and nNOS 
interactions through a direct mechanism. Both small molecules disrupt glutamate-induced 
neuronal cell death in vitro and suppress inflammatory and neuropathic pain in vivo. These 
studies identify previously unrecognized antinociceptive effects of ZL006 using models of 
inflammatory and neuropathic pain, suggesting that antinociceptive efficacy was likely due 
to disruption of NMDAR-dependent nNOS signaling pathway. We further show that a broad 
profile of antinociceptive efficacy of PSD95-nNOS inhibitors is observed following 
systemic administration in inflammatory pain models and a clinically relevant model of 
chemotherapy-induced toxic neuropathy. Moreover, PSD95-nNOS inhibitors suppressed 
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hypersensitivity in pathological pain states without altering basal nociceptive thresholds in 
the absence of the inflammatory or neuropathic pain state. Collectively, our findings suggest 
that disruption of PSD95-nNOS with small molecule inhibitors represents a valuable 
therapeutic strategy for suppressing pathological pain without unwanted side effects 
associated with NMDAR antagonism. The present studies support a therapeutic strategy of 
bypassing NMDAR inhibition by targeting downstream protein-protein interactions to 
suppress pain sensitization without producing NMDAR-associated side effects.
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Highlights
• IC87201 and ZL006 directly disrupt binding between PSD95 and nNOS in vitro.
• IC87201 and ZL006 protect against glutamate/glycine-induced neuronal cell 
death.
• Systemic IC87201 and ZL006 attenuate inflammatory and neuropathic pain 
behaviors.
• Unlike the NMDAR antagonist MK-801, IC87201 and ZL006 do not produce 
motor ataxia.
• The PSD95-nNOS protein-protein interface is a promising target for pain 
treatment.
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Figure 1. 
Chemical structures of small molecule PSD95-nNOS inhibitors IC87201 and ZL006.
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Figure 2. 
Specificity of IC87201 and ZL006 for disrupting PSD95-nNOS binding demonstrated in 
AlphaScreen. A. Titration of GST-PSD951–392 and His-nNOS1–299 from 0–175 nM. The 
EC50 determined is at 30 nM (n = 2). B. GST-PSD951–392 and His-nNOS1–299 interactions 
were disrupted by IC87201 and ZL006 with an EC50 of 23.94 µM (n = 7) and 12.88 µM (n = 
7) for IC87201 and ZL006, respectively. C. Titration of His-PSD951–392 and Biot-
ErbB41289–1309 from 0–175 nM. The EC50 determined is at 10 nM (n = 2). D. IC87201 and 
ZL006 did not disrupt Biot-ErbB41289–1308 and His-PSD951–392 protein-protein 
interactions.
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Figure 3. 
Effects of small molecule inhibitors on cortical neuronal cell death induced by glutamate. 
Pretreatment of small molecule inhibitors, IC87201 (10 µM) and ZL006 (10 µM) protected 
against glutamate treatment induced cell death in cortical neuronal cells with efficacy 
similar to MK-801 (20 µM). **p < 0.01; ***p < 0.001 (one-way ANOVA).
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Figure 4. 
Effects of small molecule PSD95-nNOS inhibitors on formalin-induced pain behaviors. A, B 
IC87201 (4 and 10 mg/kg i.p.) suppresses formalin-induced nociceptive behaviors during 
phase 2A (n = 6–8). C, D ZL006 (4 and 10 mg/kg i.p.) suppresses formalin-induced 
nociceptive behaviors during phase 1 and phase 2A but not during phase 2B (n = 6–8). E, F 
Comparison of maximally efficacious doses of small molecule inhibitors with NMDAR 
antagonist MK-801 (0.1 mg/kg i.p.) (n = 6–8). *p < 0.05; **p < 0.01; ***p < 0.001 versus 
control.
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Figure 5. 
Effects of small molecule inhibitors on CFA induced mechanical allodynia. A. IC87201 (10 
mg/kg, ip) and ZL006 (10 mg/kg, ip) suppressed CFA-induced mechanical allodynia similar 
to MK-801 (0.1 mg/kg i.p.). B. IC87201 and ZL006 administration did not alter mechanical 
thresholds in the contralateral paw. (n = 6 per group). *p < 0.05; **p <0.01; ***p <0.001. # 
p < 0.01 difference between baseline (BL) and post CFA pre-injection response.
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Figure 6. 
Dose response of small molecule inhibitors on paclitaxel-induced mechanical and cold 
allodynia. A, B. Pre-drug mechanical paw withdrawal thresholds (A) and cold response 
latencies (B) during the maintenance phase of paclitaxel-induced allodynia. Data are plotted 
relative to pre-paclitaxel baseline responding. C, D. Dose response of IC87201 and ZL006 
in suppressing paclitaxel-induced (C) mechanical and (D) cold responsiveness. E, F. % 
Maximal possible effect (%MPE) of IC87201 and ZL006 in suppressing (E) mechanical and 
(F) cold allodynia used for ED50 calculation (n = 6 per group).*p < 0.05; **p < 0.01; ***p < 
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0.001 versus vehicle. # p < 0.01 difference between baseline (BL) and post pacltiaxel (PTX) 
pre-injection response.
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Figure 7. 
Small molecule PSD95-nNOS inhibitors suppress paclitaxel-induced mechanical allodynia. 
A. Paclitaxel but not cremophor vehicle treatment induced mechanical allodynia. B. 
IC87201 (10 mg/kg, i.p) and ZL006 (10 mg/kg, i.p.) attenuate paclitaxel-induced 
mechanical allodynia, similar to MK-801 (0.1 mg/kg i.p.). C. IC87201, ZL006 and MK801 
treatment did not alter mechanical paw withdrawal thresholds in the absence of paclitaxel 
treatment. (n = 6 per group). *p < 0.05; **p < 0.01; ***p < 0.001 versus vehicle. #p < 0.01 
difference between baseline (BL) and post paclitaxel (PTX) pre-injection threshold.
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Figure 8. 
PSD95-nNOS inhibitors IC87201 and ZL006 (10 mg/kg i.p.) did not produce motor ataxia 
in the rota rod test. A high (1 mg/k i.p.) but not a low (0.1 mg/kg i.p.) dose of MK-801 
decreased latency to fall off a rotating drum in the rota-rod test. (n= 6–11 per group). **p < 
0.01 versus vehicle.
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Figure 9. 
Small molecule PSD95-nNOS inhibitors at supramaximal doses (30 mg/kg i.p.) did not 
produce tail flick antinociception/hyperalgesia or produce motor ataxia. A. IC87201 and 
ZL006 did not alter tail flick latencies whereas MK-801 (0.3 mg/kg i.p.) produced 
hyperalgesia in the same test. B. In the same animals, small molecule PSD95-nNOS 
inhibitors (30 mg/kg i.p.) did not impair motor coordination whereas MK-801 (0.3 mg/kg 
i.p.) produced robust motor ataxia. (n= 6 per group).*p < 0.05;***p < 0.001.
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